



UNIVERSITY OF SOUTHERN CALIFORNIA

**Department of Chemistry
Michelson Center for Convergent Bioscience**

Special Seminar

“Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1”

ABL001 is a potent, selective BCR-ABL1 inhibitor that maintains activity across most mutations, including T315I, with a distinct, allosteric mechanism of action. It is currently undergoing phase III clinical studies in chronic myelogenous leukemia patients. Dual allosteric and catalytic BCR-ABL1 inhibition may allow for tumor eradication in patients with CML. The structure guided discovery of ABL001 targeting the myristoyl pocket of the ABL1 kinase by integrating X-ray crystallography, NMR and molecular modeling will be discussed.

Dr. Andreas Marzinzik

Director

**Novartis Institutes for BioMedical Research
Basel, Switzerland**

Thursday, December 13, 2018

12:00 PM

MCB-101

*Hosted by Prof. Valery Fokin
fokin@usc.edu*

Scientific Community is Invited